Shopping Cart
- Remove All
- Your shopping cart is currently empty
Satralizumab (SA-237) is a humanized monoclonal antibody targeting interleukin-6 (IL-6), acting in neuromyelitis optica spectrum disorder (NMOSD). It is used in studies of neuromyelitis optica.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $213 | In Stock | |
5 mg | $538 | In Stock | |
10 mg | $868 | In Stock | |
25 mg | $1,280 | In Stock | |
50 mg | $1,730 | In Stock |
Description | Satralizumab (SA-237) is a humanized monoclonal antibody targeting interleukin-6 (IL-6), acting in neuromyelitis optica spectrum disorder (NMOSD). It is used in studies of neuromyelitis optica. |
In vivo | Satralizumab (120 mg/ biweekly, injected subcutaneously) prevents the formation and progression of thoracic descending aortic aneurysm (dTAA) in rats. [1] |
Alias | SA-237, SA237, RG-6168, RG6168 |
Cas No. | 1535963-91-7 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.